DDInter1956 DDInter1848
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Desvenlafaxine
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinidazole
Tinidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) causes {v} (Side Effect) Myositis
Myositis {u} (Side Effect) is caused by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Desvenlafaxine (Compound) and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Zalcitabine (Compound) causes Myositis (Side Effect) and Myositis (Side Effect) is caused by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Zalcitabine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Apixaban (Compound) and Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine